CORVUS PHARMACEUTICALS INC's ticker is CRVS and the CUSIP is 221015100. A total of 59 filers reported holding CORVUS PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $151,042 | +30.6% | 82,990 | +27.8% | 0.00% | – |
| Q1 2024 | $115,609 | +1.0% | 64,949 | -0.1% | 0.00% | – |
| Q4 2023 | $114,430 | +20.5% | 65,017 | 0.0% | 0.00% | – |
| Q3 2023 | $94,925 | -36.2% | 65,017 | 0.0% | 0.00% | – |
| Q2 2023 | $148,889 | +165.3% | 65,017 | +5.4% | 0.00% | – |
| Q1 2023 | $56,118 | +7.1% | 61,668 | 0.0% | 0.00% | – |
| Q4 2022 | $52,418 | +21.9% | 61,668 | +18.1% | 0.00% | – |
| Q3 2022 | $43,000 | -17.3% | 52,226 | 0.0% | 0.00% | – |
| Q2 2022 | $52,000 | -39.5% | 52,226 | 0.0% | 0.00% | – |
| Q1 2022 | $86,000 | -31.7% | 52,226 | 0.0% | 0.00% | – |
| Q4 2021 | $126,000 | -56.1% | 52,226 | -11.9% | 0.00% | – |
| Q3 2021 | $287,000 | +81.6% | 59,262 | 0.0% | 0.00% | – |
| Q2 2021 | $158,000 | +36.2% | 59,262 | +56.5% | 0.00% | – |
| Q1 2021 | $116,000 | +10.5% | 37,878 | +28.6% | 0.00% | – |
| Q4 2020 | $105,000 | -11.0% | 29,445 | 0.0% | 0.00% | – |
| Q3 2020 | $118,000 | +61.6% | 29,445 | +9.4% | 0.00% | – |
| Q2 2020 | $73,000 | +28.1% | 26,910 | 0.0% | 0.00% | – |
| Q1 2020 | $57,000 | -61.0% | 26,910 | 0.0% | 0.00% | – |
| Q4 2019 | $146,000 | +78.0% | 26,910 | -1.2% | 0.00% | – |
| Q3 2019 | $82,000 | -84.5% | 27,246 | -80.8% | 0.00% | – |
| Q2 2019 | $530,000 | -12.5% | 141,717 | -6.0% | 0.00% | – |
| Q1 2019 | $606,000 | +9.2% | 150,788 | -0.4% | 0.00% | – |
| Q4 2018 | $555,000 | -57.3% | 151,342 | -0.1% | 0.00% | – |
| Q3 2018 | $1,300,000 | -21.0% | 151,542 | +1.1% | 0.00% | – |
| Q2 2018 | $1,645,000 | +61.1% | 149,846 | +69.2% | 0.00% | – |
| Q1 2018 | $1,021,000 | +12.4% | 88,570 | +1.1% | 0.00% | – |
| Q4 2017 | $908,000 | -36.3% | 87,626 | -2.0% | 0.00% | – |
| Q3 2017 | $1,425,000 | +36.1% | 89,449 | +3.4% | 0.00% | – |
| Q2 2017 | $1,047,000 | +15.1% | 86,525 | +97.6% | 0.00% | – |
| Q1 2017 | $910,000 | +67.6% | 43,786 | +15.2% | 0.00% | – |
| Q4 2016 | $543,000 | -5.6% | 37,994 | +8.7% | 0.00% | – |
| Q3 2016 | $575,000 | +27.8% | 34,967 | +10.9% | 0.00% | – |
| Q2 2016 | $450,000 | – | 31,527 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ADAMS STREET PARTNERS LLC | 2,687,381 | $38,430,000 | 10.58% |
| Novo Holdings A/S | 3,224,046 | $46,104,000 | 4.39% |
| SPHERA FUNDS MANAGEMENT LTD. | 320,229 | $4,579,000 | 1.16% |
| Orbimed Advisors | 5,379,349 | $76,925,000 | 0.98% |
| Avoro Capital Advisors LLC | 216,619 | $3,098,000 | 0.63% |
| Rock Springs Capital Management LP | 450,000 | $6,435,000 | 0.43% |
| Cormorant Asset Management, LP | 198,526 | $2,839,000 | 0.38% |
| EverPoint Asset Management, LLC | 417,849 | $5,975,000 | 0.11% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 21,292 | $304,000 | 0.05% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 9,402 | $134,000 | 0.02% |